Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Arch Intern Med ; 151(8): 1597-602, 1991 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1872664

RESUMEN

Hypercholesterolemia is a significant risk factor for coronary heart disease, and the hypocholesterolemic effects of psyllium are well established. This placebo-controlled, parallel study compared psyllium with methylcellulose, calcium polycarbophil, and placebo as dietary adjuncts in treating mild to moderate hypercholesterolemia. Of 163 men and women recruited with serum cholesterol levels above 5.17 mmol/L (200 mg/dL), 105 completed 8 weeks of an American Heart Association step I diet and then augmented the diet with one of the fiber supplements for 8 additional weeks. Incremental differences from placebo for low-density lipoprotein cholesterol were -8.8% for psyllium, -3.2% for methylcellulose (not significant), and +8.7% for calcium polycarbophil; and for total cholesterol the differences were -4.3% for psyllium (not significant), -1.4% for methylcellulose (not significant), and +5.9% for calcium polycarbophil. Compliance was 94% to 96%, and only mild gastrointestinal side effects were observed. In managing mild to moderate hypercholesterolemia, methylcellulose and calcium polycarbophil provide little or no additional benefit, while psyllium significantly enhances the American Heart Association diet effects.


Asunto(s)
Resinas Acrílicas/uso terapéutico , Catárticos/uso terapéutico , Hipercolesterolemia/terapia , Metilcelulosa/uso terapéutico , Resinas Acrílicas/efectos adversos , Adulto , Anciano , Colesterol/sangre , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Femenino , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/dietoterapia , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Psyllium/efectos adversos , Psyllium/uso terapéutico , Distribución Aleatoria
2.
Arch Intern Med ; 150(9): 1822-7, 1990 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2203322

RESUMEN

The effects of the administration of 5.1 g of psyllium or placebo (cellulose) twice daily for 16 weeks were compared as adjuncts to a prudent diet in the management of moderate hypercholesterolemia in a parallel, double-blind study. Psyllium decreased the total cholesterol level by 5.6% and the low-density lipoprotein cholesterol level by 8.6%, whereas the levels were unchanged in the placebo group. The high-density lipoprotein cholesterol level decreased during the diet stabilization period in both groups and returned to near-baseline values by week 16. Plasma triglyceride levels did not change substantially in either group. Subject compliance to treatment was greater than 95%. These data suggest that psyllium hydrophilic mucilloid in a twice-daily regimen may be a useful and safe adjunct to a prudent diet in the treatment of moderate hypercholesterolemia.


Asunto(s)
Celulosa/uso terapéutico , Hipercolesterolemia/dietoterapia , Psyllium/uso terapéutico , Colesterol/sangre , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Humanos , Hipercolesterolemia/sangre , Masculino , Persona de Mediana Edad
3.
Clin Pharmacol Ther ; 68(3): 312-9, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11014413

RESUMEN

BACKGROUND: The effectiveness of caffeine as an adjuvant to ibuprofen has been documented in investigations of acute pain. Our objectives were to assess this agent in the treatment of tension-type headache and to establish clinical trial methods capable of assessing this agent in comparison with various tension headache treatments. Stopwatch technology was used for measurement techniques. METHODS: A randomized, double-blind, parallel, multicenter, single-dose, placebo- and active-controlled study included 301 subjects diagnosed with tension-type headache. Treatment groups included ibuprofen and caffeine, ibuprofen alone, caffeine alone, or placebo. Subjects measured onset of relief (both time to first perceptible relief and time to meaningful relief) after taking a single oral dose of their assigned medication. Pain intensity and pain relief were rated over a 6-hour study period. Overall evaluation was made on completion of all other ratings. RESULTS: Ibuprofen and caffeine administered together provided significantly greater analgesic activity than ibuprofen alone, caffeine alone, and placebo. Ibuprofen and caffeine administered together demonstrated significantly shorter times to meaningful improvement in headache relief than ibuprofen or placebo; significantly greater total analgesia than ibuprofen alone, caffeine alone, or placebo; and significantly greater peak relief than ibuprofen alone, caffeine alone, or placebo. Significantly more subjects obtained meaningful headache relief with ibuprofen and caffeine administered together than with ibuprofen alone or placebo. More patients reported complete headache relief with ibuprofen and caffeine administered together than with ibuprofen alone, caffeine alone, or placebo. Ibuprofen and caffeine administered together was rated significantly better by patients than either ibuprofen alone, caffeine alone, or placebo. No subjects ended participation in the study early because of adverse events. CONCLUSIONS: Sensitive methods have been introduced to assess differences in analgesia among over-the-counter analgesic agents in relieving tension-type headache pain. A double-blind study with this method suggests that ibuprofen and caffeine administered together provides greater analgesic effectiveness than either component alone.


Asunto(s)
Analgésicos no Narcóticos/uso terapéutico , Cafeína/uso terapéutico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Ibuprofeno/uso terapéutico , Cefalea de Tipo Tensional/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Analgésicos no Narcóticos/administración & dosificación , Analgésicos no Narcóticos/efectos adversos , Cafeína/administración & dosificación , Cafeína/efectos adversos , Estimulantes del Sistema Nervioso Central/administración & dosificación , Estimulantes del Sistema Nervioso Central/efectos adversos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Ibuprofeno/administración & dosificación , Ibuprofeno/efectos adversos , Masculino , Persona de Mediana Edad , Dimensión del Dolor
4.
Am J Clin Nutr ; 53(6): 1431-5, 1991 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1852093

RESUMEN

The ability of psyllium fiber to reduce postprandial serum glucose and insulin concentrations was studied in 18 non-insulin-dependent diabetic patients in a crossover design. Psyllium fiber or placebo was administered twice during each 15-h crossover phase, immediately before breakfast and dinner. No psyllium fiber or placebo was given at lunch, which allowed measurement of residual or second-meal effects. For meals eaten immediately after psyllium ingestion, maximum postprandial glucose elevation was reduced by 14% at breakfast and 20% at dinner relative to placebo. Postprandial serum insulin concentrations measured after breakfast were reduced by 12% relative to placebo. Second-meal effects after lunch showed a 31% reduction in postprandial glucose elevation relative to placebo. No significant differences in effects were noted between patients whose diabetes was controlled by diet alone and those whose diabetes was controlled by oral hypoglycemic drugs. Results indicate that psyllium as a meal supplement reduces proximate and second-meal postprandial glucose and insulin concentrations in non-insulin-dependent diabetics.


Asunto(s)
Glucemia/metabolismo , Diabetes Mellitus Tipo 2/dietoterapia , Fibras de la Dieta/uso terapéutico , Insulina/sangre , Psyllium/uso terapéutico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad
5.
Pediatrics ; 87(1): 18-27, 1991 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-1984613

RESUMEN

Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration therapy in 123 children, aged 4 to 28 months, hospitalized with acute diarrhea. The dosing regimen was 20 mg/kg five times daily for 5 days. Significant benefits were noted in the BSS group compared with placebo as manifested by decreases in stool frequency and stool weights and an improvement in stool consistency, significant improvement in clinical well-being, and shortening of the disease duration. Patients treated with BSS had a significant reduction in duration of hospital stay (6.9 days) compared with placebo-treated patients (8.5 days). Also, intravenous fluid requirements decreased significantly more rapidly and to a greater degree in the BSS-treated group. Bismuth subsalicylate was associated with clearance of pathogenic Escherichia coli from the stools in 100% of cases but was not different from placebo in rotavirus elimination. Bismuth subsalicylate was well tolerated with no reported adverse effects. Blood bismuth and serum salicylate levels were well below levels considered toxic. In this study, BSS provided effective adjunctive therapy for acute diarrhea, allowing children to get well sooner with less demand on the nursing and hospital staff.


Asunto(s)
Bismuto/uso terapéutico , Diarrea Infantil/tratamiento farmacológico , Compuestos Organometálicos/uso terapéutico , Salicilatos/uso terapéutico , Enfermedad Aguda , Bismuto/sangre , Preescolar , Método Doble Ciego , Infecciones por Escherichia coli/tratamiento farmacológico , Heces/citología , Heces/microbiología , Fluidoterapia , Humanos , Lactante , Tiempo de Internación , Compuestos Organometálicos/sangre , Infecciones por Rotavirus/tratamiento farmacológico , Salicilatos/sangre
6.
South Med J ; 83(10): 1131-7, 1990 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-2218650

RESUMEN

We investigated psyllium fiber supplementation as a means of enhancing the cholesterol-lowering effect of the phase I American Heart Association diet. Fifty-nine subjects with total serum cholesterol (TC) levels ranging from 5.56 to 10.24 mmol/L (215 to 396 mg/dL) were given a 2-month dietary lead-in followed by 3 months of diet only (29 subjects) or diet supplemented with 20.4 g of psyllium daily (30 subjects). Unlike women, men had a significant decrease in levels of both TC (-8.0%) and low-density lipoprotein cholesterol (LDL-C) (-10.1%) during the dietary lead-in. Psyllium supplementation resulted in an additional 5.5% reduction in the TC levels as compared to diet alone. Psyllium supplementation combined with dietary lead-in resulted in an overall 17.3% decrease in the TC and a 20.0% decrease in LDL-C for men, with decreases of 7.7% and 11.6%, respectively, for women. Psyllium effectively enhances the cholesterol-lowering effect of the phase I diet.


Asunto(s)
Alimentos Fortificados , Hipercolesterolemia/dietoterapia , Psyllium/uso terapéutico , Colesterol/sangre , LDL-Colesterol/sangre , Enfermedad Coronaria/prevención & control , Esquema de Medicación , Estudios de Evaluación como Asunto , Femenino , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/metabolismo , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Psyllium/administración & dosificación , Factores Sexuales , Estimulación Química , Factores de Tiempo , Pérdida de Peso/efectos de los fármacos
7.
JAMA ; 261(23): 3419-23, 1989 Jun 16.
Artículo en Inglés | MEDLINE | ID: mdl-2724486

RESUMEN

Psyllium hydrophilic mucilloid was examined for its ability to lower serum cholesterol levels in hypercholesterolemic patients. Seventy-five patients with mild to moderate hypercholesterolemia were evaluated in this randomized, double-blind, placebo-controlled parallel study. Patients were treated with a Step I diet for 12 weeks before receiving placebo or 3.4 g of psyllium (equivalent to 1 teaspoon) three times per day for 8 weeks. Compared with placebo, psyllium achieved an additional 4.8% reduction in total cholesterol level, 8.2% reduction in low-density lipoprotein cholesterol level, and 8.8% reduction in apolipoprotein B level. Psyllium did not significantly affect blood pressure or levels of high-density cholesterol, triglycerides, serum glucose, or iron. Reported adherence to diet and treatment was excellent, and no significant adverse side effects were noted. These results indicate psyllium hydrophilic mucilloid is an effective and well-tolerated adjunct to diet in the management of mild to moderate hypercholesterolemia.


Asunto(s)
Colesterol/sangre , Hipercolesterolemia/tratamiento farmacológico , Psyllium/uso terapéutico , Adulto , Anciano , LDL-Colesterol/sangre , Terapia Combinada , Método Doble Ciego , Femenino , Humanos , Hipercolesterolemia/dietoterapia , Masculino , Persona de Mediana Edad , Psyllium/efectos adversos , Distribución Aleatoria
8.
Pharmacology ; 30(1): 40-4, 1985.
Artículo en Inglés | MEDLINE | ID: mdl-3975255

RESUMEN

This study involved a randomized parallel groups comparison of the effects of aspirin formulated as enteric-coated granules (25 subjects) or as buffered tablets (26 subjects) with that of a lactose placebo (5 subjects), on the gastric and duodenal mucosa, as determined by endoscopic examination 2 h after a fasting single 975-mg dose. A grading scale of 0 (no damage) to 4 (severe damage) was used. The granule formulation produced a statistically significant (p less than 0.05) lower severity (mean 0.40 +/- 0.58 vs. 3.00 +/- 0.94) and incidence (36% of subjects vs. 100%) of gastric lesions than the buffered aspirin formulation. None of the lesions produced by the granule formulation or the placebo was considered clinically significant by the blinded endoscopist, whereas 17 subjects on the buffered formulation (65%) had clinically meaningful stomach damage. The incidence of duodenal lesions was minimal and comparable for the two formulations.


Asunto(s)
Aspirina/efectos adversos , Enfermedades Gastrointestinales/inducido químicamente , Adolescente , Adulto , Aspirina/administración & dosificación , Tampones (Química) , Femenino , Mucosa Gástrica/patología , Enfermedades Gastrointestinales/patología , Humanos , Mucosa Intestinal/patología , Masculino , Comprimidos Recubiertos
9.
Dig Dis Sci ; 30(6): 509-12, 1985 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-3873326

RESUMEN

When administered on a chronic high-dosage regimen, enteric-coated aspirin granules produced significantly less gastric damage than plain aspirin or aspirin-antacid combinations. Clinically meaningful damage occurred in all subjects receiving plain aspirin, 93% of those receiving aspirin-antacid combination and only 27% and 20% of those receiving enteric-coated aspirin granules qid and bid, respectively. All three aspirin formulations were taken as 1 g qid (4 g/day) and an additional group received enteric granules administered as 2 g bid (4 g/day). Gastric damage was assessed by means of endoscopy carried out after seven days of treatment. Enteric granules are equally safe when administered on a bid or qid regimen (at same total daily dosage) and, in a bid regimen, should provide a compliance advantage for patients on high-dose therapy for diseases such as rheumatoid arthritis.


Asunto(s)
Aspirina/administración & dosificación , Hemorragia Gastrointestinal/prevención & control , Úlcera Gástrica/prevención & control , Adolescente , Adulto , Aspirina/efectos adversos , Esquema de Medicación , Duodeno/patología , Femenino , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/patología , Hemorragia Gastrointestinal/inducido químicamente , Hemorragia Gastrointestinal/patología , Gastroscopía , Humanos , Masculino , Persona de Mediana Edad , Distribución Aleatoria , Estómago/patología , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/patología , Comprimidos Recubiertos
10.
J Infect Dis ; 157(5): 1008-13, 1988 May.
Artículo en Inglés | MEDLINE | ID: mdl-2896219

RESUMEN

The goals of this study were threefold: to compare the etiology of travelers' diarrhea in West Africa and Mexico, to evaluate two fecal transport systems for the recovery of enteropathogens, and to verify the efficacy of liquid bismuth subsalicylate (BSS) in different locations and under different entrance criteria for disease severity. The study populations consisted of 133 European tourists in West Africa and 112 American students in Mexico who had suffered from travelers' diarrhea. In 60% and 38% of the stool samples at the two study sites, similar proportions of enteropathogens were detected. A two-vial system consisting of Enteric Plus medium and polyvinyl alcohol fixative was slightly superior for identifying enteric pathogens than was a three-vial system with buffered glycerol saline, Cary-Blair medium with campylobacter antibodies, and polyvinyl alcohol fixative. In a parallel, double-blind, randomized trial, BSS significantly shortened disease duration at both study sites.


Asunto(s)
Diarrea , Heces , Compuestos Organometálicos/uso terapéutico , Salicilatos/uso terapéutico , Viaje , Aeromonas/aislamiento & purificación , África Occidental , Animales , Bismuto , Cryptosporidium/aislamiento & purificación , Diarrea/tratamiento farmacológico , Diarrea/etiología , Diarrea/microbiología , Entamoeba histolytica/aislamiento & purificación , Escherichia coli/aislamiento & purificación , Heces/microbiología , Heces/parasitología , Femenino , Giardia/aislamiento & purificación , Humanos , Masculino , México , Shigella/aislamiento & purificación , Manejo de Especímenes/instrumentación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA